2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 732

Impact of Disease Course on Atherosclerotic Vascular Events, Osteoporosis and Osteonecrosis in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 560

Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 323

Impact of Gains in Rheumatoid Arthritis Disease Activity Documentation on Outcomes over Time

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 500

Impact of Inflammation and Biologic Treatments on Generation and Progression to Advanced Calcified Coronary Plaques in Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 206

Impact of International Classification of Diseases 10th Revision Codes and Updated Medical Information on an Existing Rheumatoid Arthritis Phenotype Algorithm Using Electronic Medical Data

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 443

Impact of Intra-Articular Steroid Injection on Bone Marrow Lesions in Osteoarthritis of the Hip: An Assessment Using the Outcome Measures in Rheumatology Hip MRI Inflammation Scoring System

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 746

Impact of Nephritis on the Outcomes of SLE Patients Hospitalized with Acute Myocardial Infarction; Insights from the National Inpatient Sample Database

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 665

Impact of Peripheral Manifestations on Patient-Reported Outcomes (PROs) and Treatment in Spondyloarthritis. Data from ASAS-Comospa

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 219

Impact of Rheumatoid Arthritis on Influenza-Related Complications: A Population Based Cohort Study

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 326

Implementation of a Treat-to-Target Quality Improvement Program for Rheumatoid Arthritis Management Using Real-Time Patient Reported Outcome Measures

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 338

Implementation of an Automated Phrase to Increase Awareness of Cardiovascular Risk in Rheumatoid Arthritis Patients in an Urban Fellows Rheumatology Clinic

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 328

Implementation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Documentation in Systemic Lupus Erythematosus (SLE) Patients at an Academic Medical Center

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 295

Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice

Health Services Research Poster I – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 502

Implications of Coronary Artery Calcium Score and Its Change over Time As Markers of Coronary Plaque Vulnerability and Patient Risk in Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 592

Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].